Monographie - Hydralazine hydrochloride - Stabilis 4.0

Son güncelleme :
08/05/2024

Antihipertansif

Hydralazine hydrochloride

Enjeksiyon

Oral solüsyon / oral çözelti

Çözeltilerin stabilitesi

Karışımlardaki stabilitesi

Stabiliteyi etkileyen faktörler

Uyumluluk

Uygulama yöntemi

Kaynaklar

Pdf

Lipozom

Kimyasal yapı

Ticari isim

Ticari isim

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Apresoline	Kanada
Hydralazine	Amerika Birleşik Devletleri, Büyük Britanya, İspanya
Hydrapres	İspanya

Kaynaklar

Enjeksiyon

Kaynaklar : Hydralazine hydrochloride

	Tip	Yayın
660	Dergi	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
957	Dergi	Halasi S, Nairn JG. Stability studies of hydralazine in aqueous solutions. J Parenter Sci Technol 1990 ; 44: 30-34.
1049	Dergi	Klamerus KJ, Ueda CT, Newton DW. Stability of nitroglycerin in intravenous admixtures. Am J Hosp Pharm 1984 ; 41: 303-305.
1057	Dergi	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.
1173	Dergi	Kowaluk EA, Roberts MS, Blackburn HD, Polack AE. Interactions between drugs and polyvinyl chloride infusion bags. Am J Hosp Pharm 1981 ; 38: 1308-1314.
1221	Dergi	Dahlin PA, Paredes SM. Visual compatibility of dobutamine with seven parenteral drug products. Am J Hosp Pharm 1980 ; 37: 460,464.
1228	Dergi	Allen LV, Stiles ML. Compatibility of various admixtures at Y-injection sites of intravenous administration sets. Part2. Am J Hosp Pharm 1981 ; 38: 380-381.
2090	Dergi	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2233	Dergi	Condie C.K, Tyler L.S, Barker B, Canann D.M. Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.
2367	Dergi	Gupta V.D. Chemical stability of hydralazine hydrochloride after reconstitution in 0.9% sodium chloride injection or 5% dextrose injection for infusion. Int J Pharm Compound 2005 ; 9, 5: 399-401.
3012	Dergi	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3408	Dergi	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3766	Dergi	Forrest J.M, Hildgen P. Compatibilité de l’acétylcystéine injectable lors de son administration en Y avec d’autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3964	Dergi	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
4319	Dergi	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4389	Dergi	Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine. Pharmactuel 2019 ;52,4:206-213
4603	Dergi	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.

Mentions Légales